Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Granella

Showing results (41-50 of 112) with videos related to

Pageof 12
Sort By:
Journal of Neurology|September 28, 2018
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world studyLuca Prosperini, Pietro Annovazzi, Laura Boffa, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|April 12, 2021
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison StudyAurora Zanghì, Antonio Gallo, Carlo Avolio, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 21, 2018
Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosisMyintzu Min, Tim Spelman, Alessandra Lugaresi, et al.
Journal of Neurology|June 8, 2020
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysisEmanuele D'Amico, Aurora Zanghì, Mariangela Sciandra, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 9, 2020
Prediction of on-treatment disability worsening in RRMS with the MAGNIMS scoreAmy Kunchok, Jeannette Lechner-Scott, Franco Granella, et al.
Journal of Neurology|August 23, 2024
Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosisMarta Simone, Giuseppe Lucisano, Tommaso Guerra, et al.
Multiple Sclerosis and Related Disorders|October 15, 2019
Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disordersGiovanni Novi, Francesca Bovis, Marco Capobianco, et al.
Annals of Neurology|February 12, 2022
Comparing Natural History of Early and Late Onset Pediatric Multiple SclerosisErmelinda De Meo, Massimo Filippi, Maria Trojano, et al.
Neurology|August 11, 2017
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMSJohannes Lorscheider, Vilija G Jokubaitis, Tim Spelman, et al.
Annals of Clinical and Translational Neurology|July 6, 2024
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosisPietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, et al.
Pageof 12

Showing results (41-50 of 112) with videos related to

Sort By:
Pageof 12
Journal of Neurology|September 28, 2018
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world studyLuca Prosperini, Pietro Annovazzi, Laura Boffa, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|April 12, 2021
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison StudyAurora Zanghì, Antonio Gallo, Carlo Avolio, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 21, 2018
Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosisMyintzu Min, Tim Spelman, Alessandra Lugaresi, et al.
Journal of Neurology|June 8, 2020
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysisEmanuele D'Amico, Aurora Zanghì, Mariangela Sciandra, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 9, 2020
Prediction of on-treatment disability worsening in RRMS with the MAGNIMS scoreAmy Kunchok, Jeannette Lechner-Scott, Franco Granella, et al.
Journal of Neurology|August 23, 2024
Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosisMarta Simone, Giuseppe Lucisano, Tommaso Guerra, et al.
Multiple Sclerosis and Related Disorders|October 15, 2019
Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disordersGiovanni Novi, Francesca Bovis, Marco Capobianco, et al.
Annals of Neurology|February 12, 2022
Comparing Natural History of Early and Late Onset Pediatric Multiple SclerosisErmelinda De Meo, Massimo Filippi, Maria Trojano, et al.
Neurology|August 11, 2017
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMSJohannes Lorscheider, Vilija G Jokubaitis, Tim Spelman, et al.
Annals of Clinical and Translational Neurology|July 6, 2024
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosisPietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, et al.
Pageof 12